Core Viewpoint - The stock of Gossamer Bio, Inc. (01167) has seen a significant increase, rising over 6% during trading, with a current price of HKD 8.04 and a trading volume of HKD 8.1525 million. The company has received a substantial payment that enhances its cash reserves and supports its ongoing research in innovative cancer therapies [1]. Group 1 - Gossamer Bio's subsidiary, Beijing Gossamer, has received an initial payment of RMB 125 million from Haisong Capital, which bolsters the group's cash reserves [1]. - The receipt of this payment is expected to facilitate the advancement of the company's pipeline for innovative cancer therapies [1]. Group 2 - Gossamer Bio announced the publication of clinical I/IIa study results for its self-developed KRAS G12C inhibitor, Glecirasib, in combination with SHP2 inhibitor JAB-3312 (Sitneprotafib) in the prestigious medical journal, The Lancet Respiratory Medicine, which has an impact factor of 32.8 [1]. - This publication marks the first time systematic clinical data on the combination of KRAS G12C and SHP2 oral small molecule therapies has been featured in such a reputable journal [1].

Core Viewpoint - The stock of Gossamer Bio, Inc. (01167) has seen a significant increase, rising over 6% during trading, attributed to positive developments in the company's financial and clinical research activities [1] Financial Developments - Gossamer Bio's subsidiary, Beijing Gossamer, has received an initial payment of RMB 125 million from Haisong Capital, enhancing the group's cash reserves [1] - The receipt of this payment is expected to support the advancement of the company's innovative oncology therapy pipeline [1] Clinical Research Achievements - Gossamer Bio announced that the clinical I/IIa study results of its self-developed KRAS G12C inhibitor, Glecirasib, in combination with the SHP2 inhibitor, JAB-3312, have been published in the prestigious medical journal, The Lancet Respiratory Medicine [1] - This publication marks the first time systematic clinical data on the combination of KRAS G12C and SHP2 oral small molecule therapies has appeared in such a high-impact journal [1]

Core Insights - The company, Goss, announced the publication of clinical I/IIa study results for its KRAS G12C inhibitor, Glecirasib, in combination with SHP2 inhibitor, JAB-3312, in the prestigious medical journal, The Lancet Respiratory Medicine, marking the first systematic clinical data for this dual oral therapy to be featured in such a high-impact publication [1] Group 1 - The open-label clinical I/IIa study was conducted in China, enrolling 171 patients with KRAS G12C mutated non-small cell lung cancer (NSCLC), including 102 treatment-naive patients [1] - The combination therapy achieved a 71% objective response rate (ORR) and a median progression-free survival (mPFS) of 12.2 months in first-line patients, demonstrating a leading standard in KRAS G12C related first-line treatment [1] - Compared to the current standard treatment of immunotherapy plus chemotherapy, this chemotherapy alternative shows a highly competitive profile [1] Group 2 - Currently, KRAS G12C inhibitors and SHP2 inhibitors are undergoing phase III clinical trials in China, directly comparing this combination therapy with existing standard treatment pathways in first-line patients [2] - This dual oral combination is positioned to potentially become the first SHP2 combination therapy to receive global approval [2]